論文 - 仲瀬　裕志

Ectopic pancreas at the jejunum.

Yasuhiro Takeda, Hiroshi Nakase, Tsutomu Chiba

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver   43 ( 3 ) e6  2011年03月  [査読有り]  [国際誌]

DOI PubMed

Potential role of granulocyte/monocyte adsorptive apheresis for ulcerative colitis with concomitant CMV infection

H. Nakase, M. Matsuura, T. Chiba

ALIMENTARY PHARMACOLOGY & THERAPEUTICS ( WILEY-BLACKWELL )  33 ( 4 ) 497 - 498  2011年02月  [査読有り]

DOI

Clinical significance of serum diamine oxidase activity in inflammatory bowel disease: Importance of evaluation of small intestinal permeability.

Yusuke Honzawa, Hiroshi Nakase, Minoru Matsuura, Tsutomu Chiba

Inflammatory bowel diseases   17 ( 2 ) E23-5  2011年02月  [査読有り]  [国際誌]

DOI PubMed

Positive finding of colonic polymerase chain reaction for cytomegalovirus DNA is not false positive but a warning for treating patients with ulcerative colitis refractory to immunosuppressive therapies.

Hiroshi Nakase, Takuya Yoshino, Kayoko Matumura, Yusuke Honzawa, Shuji Yamamoto, Minoru Matsuura, Tsutomu Chiba

Inflammatory bowel diseases   17 ( 2 ) E13-4  2011年02月  [査読有り]  [国際誌]

DOI PubMed

Tacrolimus: rescue therapy or experimental drug for severe ulcerative colitis?

H. Nakase, S. Yamamoto, M. Matsuura, T. Chiba

ALIMENTARY PHARMACOLOGY & THERAPEUTICS ( WILEY-BLACKWELL PUBLISHING, INC )  33 ( 3 ) 413 - 414  2011年02月  [査読有り]

DOI

Role of heat shock protein 47 in intestinal fibrosis of experimental colitis.

Hiroshi Kitamura, Shuji Yamamoto, Hiroshi Nakase, Minoru Matsuura, Yusuke Honzawa, Kayoko Matsumura, Yasuhiro Takeda, Norimitsu Uza, Kazuhiro Nagata, Tsutomu Chiba

Biochemical and biophysical research communications ( ACADEMIC PRESS INC ELSEVIER SCIENCE )  404 ( 2 ) 599 - 604  2011年01月  [査読有り]  [国際誌]

　概要を見る

BACKGROUND AND AIMS: Intestinal fibrosis is a clinically important issue of inflammatory bowel disease (IBD). It is unclear whether or not heat shock protein 47 (HSP47), a collagen-specific molecular chaperone, plays a critical role in intestinal fibrosis. The aim of this study is to investigate the role of HSP47 in intestinal fibrosis of murine colitis. METHODS: HSP47 expression and localization were evaluated in interleukin-10 knockout (IL-10KO) and wild-type (WT, C57BL/6) mice by immunohistochemistry. Expression of HSP47 and transforming growth factor-β1 (TGF-β1) in colonic tissue was measured. In vitro studies were conducted in NIH/3T3 cells and primary culture of myofibroblasts separated from colonic tissue of IL-10KO (PMF KO) and WT mice (PMF WT) with stimulation of several cytokines. We evaluated the inhibitory effect of administration of small interfering RNA (siRNA) targeting HSP47 on intestinal fibrosis in IL-10KO mice in vivo. RESULTS: Immunohistochemistry revealed HSP47 positive cells were observed in the mesenchymal and submucosal area of both WT and IL-10 KO mice. Gene expressions of HSP47 and TGF-β1 were significantly higher in IL-10KO mice than in WT mice and correlated with the severity of inflammation. In vitro experiments with NIH3T3 cells, TGF-β1 only induced HSP47 gene expression. There was a significant difference of HSP47 gene expression between PMF KO and PMF WT. Administration of siRNA targeting HSP47 remarkably reduced collagen deposition in colonic tissue of IL-10KO mice. CONCLUSIONS: Our results indicate that HSP47 plays an essential role in intestinal fibrosis of IL-10KO mice, and may be a potential target for intestinal fibrosis associated with IBD.

DOI PubMed J-GLOBAL

[Non-epithelial tumors of the small intestine].

Hiroshi Nakase, Shuji Yamamoto, Minoru Matsuura, Tsutomu Chiba

Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine   100 ( 1 ) 113 - 8  2011年01月  [査読有り]  [国内誌]

PubMed

Effect and safety of granulocyte-monocyte adsorption apheresis for patients with ulcerative colitis positive for cytomegalovirus in comparison with immunosuppressants.

Takuya Yoshino, Hiroshi Nakase, Minoru Matsuura, Kayoko Matsumura, Yusuke Honzawa, Takumi Fukuchi, Kenji Watanabe, Mitsuyuki Murano, Tomoyuki Tsujikawa, Ken Fukunaga, Takayuki Matsumoto, Tsutomu Chiba

Digestion ( KARGER )  84 ( 1 ) 3 - 9  2011年  [査読有り]  [国際誌]

　概要を見る

BACKGROUND: Cytomegalovirus (CMV) infection exacerbates ulcerative colitis (UC) refractory to immunosuppressive therapies (IMT). However, the underlying UC remained active in some UC patients, despite the fact that CMV-DNA in colonic mucosa became negative after antiviral therapy. Therefore, new therapeutic strategies for UC patients concomitant with CMV infection in mucosa are required. AIMS: The aim of this study was to evaluate the effect and safety of granulocyte-monocyte adsorption apheresis (GMA) in UC patients positive for CMV infection after antiviral therapy. METHODS: From October 2003 to December 2008, 64 patients with UC refractory to IMT, including steroids and immunomodulators, were enrolled in this retrospective, observational, multicenter study, which was reviewed and approved by the Institutional Review Board of Kyoto University. CMV infection was investigated by 3 methods (histologic examination, CMV antigenemia, and polymerase chain reaction). We investigated the clinical outcomes of GMA and IMT after 2 weeks of treatment with ganciclovir. RESULTS: Thirty-one (48.4%) of 64 patients with UC refractory to IMT were positive for CMV. Of the 31 patients, 4 (12.9%) underwent colectomy. Twenty-seven patients (87.1%) underwent antiviral therapy. Of those 27 patients, 7 achieved remission following antiviral therapy alone. Of the remaining 20 patients who did not achieve remission despite the disappearance of CMV-DNA, 11 and 9 patients were treated with additional GMA (GMA group) and IMT (IMT group), respectively. Of 11 patients (GMA group), 9 achieved remission and 2 underwent colectomy. Out of the remaining 9 patients (IMT group), 4 achieved remission and 5 underwent colectomy. CMV-DNA was not detected in 11 patients after GMA, but it was detected again in all 5 patients of the IMT group who underwent colectomy. The total colectomy rate in UC patients positive for CMV was 35.5% (11/31). In addition, colectomy-free survival in the CMV relapse (+) group was estimated to be 12.9% at 65 months, while that in the CMV relapse (-) group was estimated to be 100% at 60 months. CONCLUSION: The colectomy ratio tends to be high in refractory UC patients with recurrent CMV reactivation or infection. Therefore, GMA might be a safe and effective treatment for UC patients positive for CMV because it does not induce CMV reactivation.

DOI PubMed

Patients with crohn\\'s disease have hypovitaminosis D and K, which is independent of general malnutrition

A. Kuwabara, N. Tsugawa, M. Kamao, H. Nakase, T. Chiba, T. Okano, K. Tanaka

Vitamin D: Nutrition, Side Effects and Supplements     155 - 164  2011年  [査読有り]

Immunosuppressive effects of tacrolimus on macrophages ameliorate experimental colitis.

Takuya Yoshino, Hiroshi Nakase, Yusuke Honzawa, Kayoko Matsumura, Shuuji Yamamoto, Yasuhiro Takeda, Satoru Ueno, Norimitsu Uza, Satohiro Masuda, Kenichi Inui, Tsutomu Chiba

Inflammatory bowel diseases ( JOHN WILEY & SONS INC )  16 ( 12 ) 2022 - 33  2010年12月  [査読有り]  [国際誌]

　概要を見る

BACKGROUND: Tacrolimus is a novel immunomodulator for inflammatory bowel diseases. Immunosuppressive effects of tacrolimus on T cells are well known; however, the effects of tacrolimus on macrophages remain unclear. The aim of this study was to investigate the effects of tacrolimus on activated macrophages and to examine its efficacy in murine colitis models. METHODS: Proinflammatory cytokine production from lipopolysaccharide (LPS)-stimulated peritoneal macrophages of IL-10-knockout (KO) mice with and without tacrolimus was measured. We investigated the effects of tacrolimus on nuclear factor-κB (NF-κB), mitogen-activated protein kinase (MAPK), and caspase activation in macrophages and the induction of apoptosis in macrophages in vitro and examined the in vivo apoptotic effect of tacrolimus on colonic macrophages in IL-10-KO mice. We evaluated the effect of the rectal administration of tacrolimus on colonic inflammation in IL-10-KO mice and dextran sulfate sodium (DSS)-induced colitis in CB.17/SCID mice. RESULTS: Proinflammatory cytokine production from tacrolimus-treated macrophages was significantly lower than that from untreated cells. Tacrolimus suppressed LPS-induced activation of both NF-κB and MAPK in macrophages and induced apoptosis of macrophages via activation of caspases 3 and 9. Rectal administration of tacrolimus evoked apoptosis of colonic macrophages in IL-10-KO mice. Moreover, the rectal administration of tacrolimus ameliorated colitis in IL-10-KO mice and DSS-induced colitis in CB.17/SCID mice. Gene expression of inflammatory cytokines in colonic mucosa was significantly lower in tacrolimus-treated mice than in untreated mice. CONCLUSIONS: Tacrolimus suppresses the function of activated macrophages and promotes their apoptosis, which may lead to the amelioration of colonic inflammation.

DOI PubMed

Heat shock protein 47 can be a new target molecule for intestinal fibrosis related to inflammatory bowel disease.

Yusuke Honzawa, Hiroshi Nakase, Yasuhiro Takeda, Kazuhiro Nagata, Tsutomu Chiba

Inflammatory bowel diseases ( JOHN WILEY & SONS INC )  16 ( 12 ) 2004 - 6  2010年12月  [査読有り]  [国際誌]

DOI PubMed

炎症性腸疾患の病態に基づいた治療法の開発 実験腸炎に対するシクロスポリン封入マイクロスフェアーの治療

深田憲将, 内田一茂, 大宮美香, 松下光伸, 仲瀬裕志, 千葉勉, 田畑泰彦, 岡崎和一

月刊消化器内科 ( 科学評論社 )  51 ( 4 ) 336 - 340  2010年10月  [査読有り]

CiNii

Successful Endoscopic Dilation Treatment of Small Intestinal Stricture Occurring during Chemotherapy for Malignant Lymphoma.

Yusuke Honzawa, Masahiko Kondo, Takanobu Hayakumo, Minoru Matsuura, Hiroshi Nakase

Case reports in gastroenterology   4 ( 3 ) 323 - 329  2010年09月  [査読有り]  [国際誌]

　概要を見る

We report a stricture occurring during chemotherapy for malignant lymphoma that was successfully treated by endoscopic balloon dilation. The patient was diagnosed with stage IV malignant lymphoma by esophagogastroduodenoscopy and computed tomography scans. She complained of nausea and vomiting after undergoing the second cycle of chemotherapy. A small intestinal series through an ileus tube showed severe stricture of the ileum. Endoscopic balloon dilation was successfully performed with single-balloon endoscopy. After the procedure, her symptoms subsided and did not recur even 8 months after endoscopic dilation therapy.

DOI PubMed

Cytomegalovirus affects clinical outcome of infliximab in ulcerative colitis refractory to tacrolimus

H. Nakase, S. Yamamoto, M. Matsuura, Y. Honzawa, T. Chiba

ALIMENTARY PHARMACOLOGY & THERAPEUTICS ( WILEY-BLACKWELL )  32 ( 3 ) 510 - 511  2010年08月  [査読有り]

DOI

Pedunculated cavernous hemangioma mimicking inflammatory fibroid polyp in a patient with ulcerative colitis

K. Ueda, H. Nakase, H. Yaku, Y. Honzawa, T. Chiba

ENDOSCOPY ( GEORG THIEME VERLAG KG )  42 ( SUPPL. 2 ) E162 - E162  2010年07月  [査読有り]

DOI PubMed

Modulation of Th1/Th2 balance by infliximab rescues postoperative occurrence of small-intestinal inflammation associated with ulcerative colitis.

Reiko Akitake, Hiroshi Nakase, Masashi Tamaoki, Satoru Ueno, Sakae Mikami, Tsutomu Chiba

Digestive diseases and sciences ( SPRINGER )  55 ( 6 ) 1781 - 4  2010年06月  [査読有り]  [国際誌]

DOI PubMed CiNii J-GLOBAL

Effect of EP4 agonist (ONO-4819CD) for patients with mild to moderate ulcerative colitis refractory to 5-aminosalicylates: a randomized phase II, placebo-controlled trial.

Hiroshi Nakase, Yoshihide Fujiyama, Nobuhide Oshitani, Toru Oga, Kimiko Nonomura, Toshiyuki Matsuoka, Yoshiyasu Esaki, Toshinori Murayama, Satoshi Teramukai, Tsutomu Chiba, Shuh Narumiya

Inflammatory bowel diseases ( JOHN WILEY & SONS INC )  16 ( 5 ) 731 - 3  2010年05月  [査読有り]  [国際誌]

DOI PubMed

Sustained abdominal discomfort in a 57-year-old woman. Idiopathic mesenteric phlebosclerosis.

Hisayo Nishiura, Hiroshi Nakase, Tsutomu Chiba

Gut ( B M J PUBLISHING GROUP )  59 ( 5 ) 578, 594 - +  2010年05月  [査読有り]  [国際誌]

DOI PubMed

Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus.

Shuji Yamamoto, Hiroshi Nakase, Minoru Matsuura, Yusuke Honzawa, Satohiro Masuda, Ken-ichi Inui, Tsutomu Chiba

Journal of gastroenterology and hepatology ( WILEY-BLACKWELL )  25 ( 5 ) 886 - 91  2010年05月  [査読有り]  [国際誌]

　概要を見る

BACKGROUND AND AIM: Little is known about the efficacy and safety of infliximab for ulcerative colitis refractory to tacrolimus. The aim of this study was to evaluate the efficacy and safety of infliximab in the induction of remission in ulcerative colitis patients with persistent symptoms despite tacrolimus therapy. METHODS: We report a retrospective, observational, single-center case series of 12 consecutively enrolled patients with ulcerative colitis refractory to tacrolimus that received infliximab therapy for the induction of remission. Eight patients received a single infusion of infliximab, and four received two or more infusions. Median follow-up duration was 16.0 months (range, 1.6-41.4 months). The clinical response was evaluated based on a modified Truelove-Witts severity index. RESULTS: Six patients (50.0%) achieved clinical remission within 30 days. Overall cumulative colectomy-free survival was estimated to be 58.3% at 41.4 months. Adverse events included an elevation of liver enzymes (1/12; 8.3%) and a mild infusion reaction (1/12; 8.3%). No mortality occurred. CONCLUSIONS: Infliximab can induce remission in patients with ulcerative colitis who do not tolerate or respond to tacrolimus therapy.

DOI PubMed

Low prevalence of CMV infection in patients with Crohn's disease in comparison with ulcerative colitis: effect of different immune response on prevalence of CMV infection.

Hiroshi Nakase, Takuya Yoshino, Yusuke Honzawa, Tsutomu Chiba

Digestive diseases and sciences ( SPRINGER )  55 ( 5 ) 1498 - 9  2010年05月  [査読有り]  [国際誌]

DOI PubMed